## **SUPPLEMENTARY DATA TO:**

# A four-subunit DNA polymerase $\zeta$ complex containing Pol $\delta$ accessory subunits is essential for PCNA-mediated mutagenesis

Alena V. Makarova, Joseph L. Stodola, and Peter M. Burgers\*

Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA

Running Title: A four-subunit Pol ζ complex in mutagenesis

\*corresponding author: TEL: (314) 362-3872 FAX: (314) 362-71831 E-mail: <u>burgers@biochem.wustl.edu</u>

### **Materials and Methods**

Strains.

The protease deficient yeast strain FM113 (a haploid version of BJ2168; *MAT***a**: *leu2–3,112*, *pep4–3*, *prb1–1122*, *prc1–407*, *trp1–289*, *ura3–52*), Pol32 deficient strain PY117 (*MAT***a**: *his3-11*, *15*, *leu2–3,112*, *nuc1*\Delta::*LEU2*, *pep4–3*, *pol32*\Delta::*HIS3*, *prb1–1122*, *trp1–*Δ, *ura3–52*) and Rev1 deficient strain PY201 (*MAT* $\alpha$ : *arg4-17*, *his3*\Delta*-1*, *leu2-3*, *112*, *trp1*, *ura3-52*, *rev1::HISG*) were used for overexpression of Pol  $\zeta_4$  and Pol  $\zeta_2$  complexes. Strain PJ69-4A (MAT**a**: gal4- $\Delta$ , gal80- $\Delta$ , his3- $\Delta$ 200, leu2-3, 112, LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ, trp1-901, ura3-52) was used for two-hybrid analysis.

#### Plasmids

The plasmids used in this study are listed in Supplementary Table 1. The pBL813 plasmid encodes *REV3* and *REV7* genes optimized to yeast codon usage. *REV3opt* and *REV7opt* genes were chemically synthesized by GenScript (NJ). Mutations in *REV3* gene were obtained by site-directed mutagenesis using the Quick Change mutagenesis kit (Stratagene). Plasmids and sequences are available upon request.

Supplementary	Table 1.	Plasmids
---------------	----------	----------

name	plasmid	description referer	
pBL346	pRS425-GAL-POL31-POL32	expression of Pol31 and Pol32 under	this work
		GAL1-10	
pBL347	pRS425-GAL-HIS-POL31-	expression of 7xHIS-Pol31 and Pol32	this work
	POL32	under GAL1-10	
pBL348	pRS425-GAL-HIS-POL31-	expression of 7xHIS-Pol31 and Pol32	this work
	$POL32^{\Delta PIP}$	under GAL1-10	
pBL811	pRS426-GAL-GST-REV3	expression of wild type GST-Rev3 under	(28)
		GAL1-10	
pBL811-A1	pRS426-GAL-GST-REV3 <sup>C1401S,</sup>	expression of cysA-GST-Rev3 under	this work
	C1417S	GAL1-10	
pBL811-A2	pRS426-GAL-GST-	expression of cysA`-GST-Rev3 under	this work
_	REV3 <sup>C1401A, C1417A</sup>	GAL1-10	
pBL811-B	pRS426-GAL-GST-REV3 <sup>C1449S,</sup>	expression of cysB-GST-Rev3 under	this work
	- C1473S	GAL1-10	
pBL812	pRS424-GAL-REV7	expression of Rev7 under GAL1-10	this work
pBL813	pRS426-GAL-GST-REV3opt-	expression of wild type GST-Rev3 and	this work
	REV7opt	Rev7 under GAL1-10 using codon-	
		optimized genes	
pBL816	pGBT8-BD-REV3	yeast two hybrid plasmid encoding for	this work
		wild type Rev3 in a frame with GAL4	
		DNA binding domain	
pBL816-A	pGBT8-BD-REV3 <sup>C1401S, C1417S</sup>	yeast two hybrid plasmid encoding for this work	
		cysA-Rev3 in a frame with GAL4 DNA	
		binding domain	
pBL816-B	pGBT8-BD-REV3 <sup>C1449S, C1473S</sup>	yeast two hybrid plasmid encoding for	this work
		cysB-Rev3 in a frame with GAL4 DNA	
		binding domain	
pBL817	pACT2-AD-REV7	yeast two hybrid plasmid encoding for	this work
		Rev7 in a frame with GAL4 activation	
		domain	
pBL364	pACT2-AD-POL31	yeast two hybrid plasmid encoding for	(16)
		Pol31 in a frame with GAL4 activation	
		domain	
pBL391	pACT2-AD-POL32	yeast two hybrid plasmid encoding for	(16)
		Pol32 in a frame with GAL4 activation	
		domain	

*Expression and purification of four and two subunit Pol*  $\zeta$  *complexes* 

Stoichiometric and nonstoichiometric Pol  $\zeta_4$  and Pol  $\zeta_2$  complexes were produced in strains BJ2168, PY117 or PY201 and purified as described previously with modifications (26). Galactose induction was performed at OD<sub>660</sub>  $\geq$ 3 and cells were grown for another 10-12 h. 500 - 800 g of cells were resuspended in 3x lysis buffer (150 mM Hepes (pH 7.8), 900 mM KCl, 90 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.8), 6% glycerol, 7.5 mM sucrose, 0.15% Tween 20, 0.03% Nonidet P40, 6 mM DTT, 30 µM pepstatin A, 30 µM leupeptin, 7.5 mM benzamidine) and disrupted in a blender with dry ice. All further steps were carried out at 0–4 °C. When the powder was dissolved, PMSF was added to the suspension to 0.5 mM and glycerol was adjusted to final 8%. To precipitate nucleic acids 45 ml of 10% Polymin P was added per one liter of lysate and the mixture was stirred for 20 min. After preclearing of lysate at 18,000 rpm for 25 min, 0.31 g/ml ammonium sulfate was added to the supernatant and the mixture was stirred for another 20-30 min. The pellet was collected at 18,000 for 20 min and dissolved in 750-1200 ml of buffer A1 (50 mM Hepes (pH 7.4), 300 mM KCl, 30 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.4), 8% glycerol, 2.5 mM sucrose, 0.05% Tween 20, 0.01% Nonidet P-40, 2 mM DTT, 8 µM pepstatin A, 8 µM leupeptin, 2 mM benzamidine, 0.5 mM PMSF) and gently agitated with 2.5 ml of glutathione sepharose

beads (GE Healthcare) for 2 hours. The beads were packed into a disposable BioRad column and washed with 200 ml of buffer A1, followed by 200 ml of A2 (30 mM Hepes (pH 7.8), 200 mM KCl, 30 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.8), 8% glycerol, 2.5 mM sucrose, 0.05% Tween 20, 0.01% Nonidet P-40, 1 mM DTT, 5 mM MgCl<sub>2</sub>, 1 mM ATP, 2 µM pepstatin A, 0.5 mM PMSF), and buffer A3 (30 mM Hepes (pH 8), 100 mM KCl, 30 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 8), 8% glycerol, 2.5 mM sucrose, 0.05% Tween 20, 0.01% Nonidet P-40, 1 mM DTT, 2 µM pepstatin A, 0.5 mM PMSF). Proteins were eluted by 4-5 stepwise washes with 2 ml of buffer A3 containing 30 mM of reduced glutathione. Fractions were combined and digested overnight at 4 °C with PreScission protease. The proteins were diluted 2-fold with buffer B0 (30 mM Hepes (pH 7.4), 5% glycerol, 2.5 mM sucrose, 1 mM DTT, 0.01% E10-C12 detergent) and loaded onto a 1-ml heparin agarose column. After washing the column with buffer B1 (30 mM Hepes (pH 7.4), 150 mM KCl, 10 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.4), 5% glycerol, 2.5 mM sucrose, 1 mM DTT, 0.01% E10-C12), the proteins were eluted by step-gradient with buffer B2 (30 mM Hepes (pH 7.4), 750 mM KCl, 20 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.4), 5% glycerol, 2.5 mM sucrose, 1 mM DTT, 0.01% E10-C12). Full stoichiometric Pol  $\zeta_4$  was purified as described above, except that a metal-chelate affinity chromatography was performed instead of heparin column step. Fractions with PreScission protease-digested protein were diluted 2-fold with buffer E (30 mM Hepes (pH 7.4), 200 mM KCL, 20 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> (pH 7.4) 5% glycerol, 2.5 mM sucrose, 1 mM DTT, 0.01% E10-C12, 0.5 mM PMSF) containing 10mM imidazole and incubated with 2 ml of Ni-NTA agarose beads (Qiagen) for 45 min. The beads were packed into a column, washed with 400 ml of buffer E with 20 mM imidazole and eluted with buffer E containing 200 mM imidazole. All final preparations were dialyzed against buffer D (30 mM Hepes (pH 7.4), 200 mM NaCl, 8% glycerol, 1 mM DTT).







**Figure S2:** DNA polymerase activity of Pol $\zeta_4$  and Pol $\zeta_2$  complexes. **(A)** Basal DNA polymerase activity of Pol $\zeta_4$ , Pol $\zeta_2$ , CysA-Pol $\zeta_4$ , CysB-Pol $\zeta_2$  and Pol $\zeta_4$  - $\Delta$ PIP on activated calf thymus DNA. **(B)** Stimulation of translesion bypass activity of Pol $\zeta_4$  by ubiquitinated and nonubiquitinated PCNA on oligonucleotide substrate with an abasic site. For these experiments we used a split version of PCNA, that is fully functional in vivo, but allows for the facile addition of ubiquiting at position 164 (1). **(C)** Stimulation of DNA polymerase activity of Pol $\zeta_4$  - $\Delta$ PIP and Pol $\zeta_4$  by wild type PCNA and by mutant pcna-113 on primed circular bluescript SKII DNA.

#### **Supplementary Reference**

47. Freudenthal, B.D., Gakhar, L., Ramaswamy, S. and Washington, M.T. (2010) Structure of monoubiquitinated PCNA and implications for translesion synthesis and DNA polymerase exchange. *Nat Struct Mol Biol*, 17, 479-484.